Since NF-κB upregulates several important antiapoptotic genes, it seems plausible that an increase in NF-κB activity after antiandrogen treatment actually provides a survival advantage to metastasizing prostate cancer cells. The gene discussed is NFKB1; the disease is prostate carcinoma.